Analytical Data
-
Gene name
HLA-DRA1*01:01&HLA-DRB1*1501&MBP(ENPVVHFFKNIVTPR) Monomer
- Application
-
Alternative Names
HLA-DRA1*0101 & HLA-DRB1*1501 & MBP(ENPVVHFFKNIVTPR)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
CAI2388006.1 (I26-E216)&CAI2388008.1
-
Expression Region
CAI2388006.1 (I26-E216)&CAI2388008.1 (G30-K227)&ENPVVHFFKNIVTPR
-
Molecular Weight
37-40 kDa and 32-37 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-DRA1*01:01 and HLA-DRB1*1501 allele combination in relation to the myelin basic protein (MBP) epitope ENPVVHFFKNIVTPR is of significant interest due to its implications in autoimmune diseases, particularly multiple sclerosis (MS). HLA-DRB1*1501 is one of the most strongly associated genetic risk factors for MS, suggesting that it may enhance the presentation of specific myelin-derived peptides, leading to inappropriate T-cell activation and subsequent autoimmune pathology. The MBP peptide ENPVVHFFKNIVTPR, a critical component of the myelin sheath, is frequently implicated in the disease process. By studying the monomeric recombinant protein complex formed by HLA-DRA1*01:01 and HLA-DRB1*1501 presenting the MBP(ENPVVHFFKNIVTPR) epitope, researchers aim to elucidate the molecular mechanisms underlying T-cell activation in MS. This investigation could provide insights into how specific HLA alleles influence antigen processing and presentation, as well as how this process can lead to detrimental immune responses. Ultimately, understanding this complex interplay may pave the way for the development of targeted immunotherapeutic strategies aimed at modulating the immune response in MS patients, potentially leading to more effective treatments and improved patient outcomes.
